Literature DB >> 8214170

The DST as a predictor of outcome in depression: a meta-analysis.

S C Ribeiro1, R Tandon, L Grunhaus, J F Greden.   

Abstract

OBJECTIVE: The authors undertook a review of the literature on the dexamethasone suppression test (DST) as a predictor of course and outcome in major depression, to illustrate clinical and pathophysiological implications of studying the relation between biological measures and course of illness in psychiatry.
METHOD: In computerized searches and cross-references, 144 articles were found that related DST results to prediction of treatment response or outcome. Meta-analysis was performed on pooled data from all of the studies and separately on data from selected studies that had used stricter methodology.
RESULTS: 1) Baseline DST status did not predict response to antidepressant treatment or outcome after hospital discharge. 2) Non-suppression of cortisol on the baseline DST predicted poorer response to placebo. 3) Persistent nonsuppression of cortisol on the DST after treatment was associated with high risk of early relapse and poor outcome after discharge.
CONCLUSIONS: Baseline DST results may be devoid of prognostic value, but posttreatment nonsuppression of cortisol on the DST is strongly associated with poor outcome. Persistent nonsuppression may reflect a partially treated index episode or identify sicker patients who are unresponsive to treatment. The findings reiterate the importance of studying biological measures in relation to multiple validators of psychiatric illness beyond cross-sectional diagnosis.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8214170     DOI: 10.1176/ajp.150.11.1618

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  43 in total

1.  Expression of glucocorticoid receptor and early growth response gene 1 during postnatal development of two inbred strains of mice exposed to early life stress.

Authors:  Sylvia Navailles; Ross Zimnisky; Claudia Schmauss
Journal:  Dev Neurosci       Date:  2010-05-05       Impact factor: 2.984

Review 2.  The hypothalamic-pituitary-adrenal axis and serotonin abnormalities: a selective overview for the implications of suicide prevention.

Authors:  Maurizio Pompili; Gianluca Serafini; Marco Innamorati; Anne Maria Möller-Leimkühler; Giancarlo Giupponi; Paolo Girardi; Roberto Tatarelli; David Lester
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2010-02-20       Impact factor: 5.270

Review 3.  [New insights into the pathogenesis and pathophysiology of depression].

Authors:  C Schüle; T C Baghai; R Rupprecht
Journal:  Nervenarzt       Date:  2007-11       Impact factor: 1.214

4.  Regional alterations in the endocannabinoid system in an animal model of depression: effects of concurrent antidepressant treatment.

Authors:  Matthew N Hill; Erica J Carrier; Ryan J McLaughlin; Anna C Morrish; Sarah E Meier; Cecilia J Hillard; Boris B Gorzalka
Journal:  J Neurochem       Date:  2008-07-15       Impact factor: 5.372

Review 5.  Placebo effects: clinical aspects and neurobiology.

Authors:  Barry S Oken
Journal:  Brain       Date:  2008-06-21       Impact factor: 13.501

6.  Clomipramine in vitro reduces glucocorticoid receptor function in healthy subjects but not in patients with major depression.

Authors:  Livia A Carvalho; Mario F Juruena; Andrew S Papadopoulos; Lucia Poon; Rob Kerwin; Anthony J Cleare; Carmine M Pariante
Journal:  Neuropsychopharmacology       Date:  2008-03-26       Impact factor: 7.853

7.  Sensitization of the Hypothalamic-Pituitary-Adrenal Axis in a Male Rat Chronic Stress Model.

Authors:  Alier J Franco; Chun Chen; Tyler Scullen; Andrea Zsombok; Ahmed A Salahudeen; Shi Di; James P Herman; Jeffrey G Tasker
Journal:  Endocrinology       Date:  2016-04-07       Impact factor: 4.736

8.  Developments in psychoneuroendocrinology: a tribute to the research of Robert A Cleghorn, 1904-1995.

Authors:  S N Young
Journal:  J Psychiatry Neurosci       Date:  1995-07       Impact factor: 6.186

Review 9.  Future antidepressants: what is in the pipeline and what is missing?

Authors:  Fokko J Bosker; Ben H C Westerink; Thomas I F H Cremers; Marjolein Gerrits; Marieke G C van der Hart; Sjoukje D Kuipers; Gieta van der Pompe; Gert J ter Horst; Johan A den Boer; Jakob Korf
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

Review 10.  Glucocorticoid dysregulations and their clinical correlates. From receptors to therapeutics.

Authors:  Andrea H Marques; Marni N Silverman; Esther M Sternberg
Journal:  Ann N Y Acad Sci       Date:  2009-10       Impact factor: 5.691

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.